abstract |
A dosage regimen for the treatment of a Flaviviradae infection is described, including a viral hepatitis C infection, which includes administering gemcitabine (or its salt, prodrug or derivative, as described herein) in a dose range of Approximately 50 mg / m2 per day for an interval between one and seven days (for example, 1, 2, 3, 4, 5, 6, or 7 days) followed by a cessation of therapy. Optionally, viral load is monitored with respect to time, and after cessation, viral rebound is monitored. The therapy is not restarted unless a significant viral load is observed again, and then the therapy is repeated for 1-7 days, and more preferred, 1,2, or 3 days. This therapy can be continued indefinitely to monitor and maintain the patient's health. |